Quelles sont les études scientifiques concernant le CBD? Bibliographie complète

Bibliographie CBD complète - Màj avril 2021 - 

CBD Horizon met à votre disposition le travail de compilation de la bibliographie des études cliniques de qualité que nous avons élaboré. C'est sur cette base que nous rédigeons nos articles pour vous délivrer une information de qualité . Nous croyons que toute information doit reposer sur des bases sérieuses, nous tenons à préserver votre bien être et votre santé car la consommation de CBD impacte sur ces derniers. Ce travail est aussi pour vous n'hésitez pas à vous y référer !

Mona

  1. Agirregoitia E. ; Ibarra-Lecue I. ; Totorikaguena L. ; Mendoza R. ; Expósito A. ; Matorras R. ; Urigüen L. ; Agirregoitia, N. (2015). “Dynamics of expression and localization of the cannabinoid system in granulosa cells during oocyte nuclear maturation.” Fertil Steril 2015;104(3):753- 60. PMID: 26144572 ; DOI: 10.1016/j.fertnstert.2015.06.013
  2. Ben-Shabat, S. ; Fride, E. ; Sheskin, T. ; et al. (1998). “An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity”. Eur J Pharmacol. 1998; 353:23–31. PMID: 9721036 ; DOI: 10.1016/s0014-2999(98)00392-6
  3. Berman, P.; Futoran, K.; Lewitus, G. M.; Mukha, D.; Benami, M.; Shlomi, T.; Meiri, D. (2018) “A new ESI- LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in cannabis”. Sci. Rep., 2018, 8(1), 14280. DOI: 10.1038/s41598-018-32651-4
  4. Blasco-Benito, S. ; Seijo-Vila, M. ; Caro-Villalobos, M. ; et al. (2018). “Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer”. Biochemical Pharmacology, Volume 157, 2018, Pages 285-293. PMID: 29940172 ; DOI: 10.1016/j.bcp.2018.06.025
  5. Booth J.K.; Bohlmann, J. (2019) “Terpenes in Cannabis sativa – From plant genome to humans”. Plant Science, Volume 284, 2019, Pages 67-72. DOI: 10.1016/j.plantsci.2019.03.022
  6. De Petrocellis, L. ; et al. (2008). “Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8”. J. Pharmacol. Exp. Ther. 325, 1007–1015. DOI: 10.1124/jpet.107.134809
  7. Di Giacomo, D.; De Domenico, E.; Sette, C.; Geremia, R.; Grimaldi, P. (2016). “Type 2 cannabinoid receptor contributes to the physiological regulation of spermatogenesis.” FASEB Journal, 30, 1453–1463. PMID: 26671998 ; DOI: 10.1096/fj.15-279034
  8. Di Marzo, V.; et al. (2004). “The endocannabinoid system and its therapeutic exploitation”. Nat. Rev. Drug Discov. 3, 771–784. PMID: 15340387 ; DOI: 10.1038/nrd1495
  9. Eggers, C.; Fujitani, M.; Kato, R.; Smid, S. (2019) “Novel cannabis flavonoid, cannflavin A displays both a hormetic and neuroprotective profile against amyloid β-mediated neurotoxicity in PC12 cells: Comparison with geranylated flavonoids, mimulone and diplacone”. Biochemical Pharmacology, Volume 169, 2019. DOI: 10.1016/j.bcp.2019.08.011
  10. Elphick, M.R.; Egertová, M. (2001). “The neurobiology and evolution of cannabinoid signalling”. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. March 2001, 356 (1407): 381–408. PMID: 11316486 ; DOI: 10.1098/rstb.2000.0787
  11. El-Talatini, M.R.; Taylor, A.H.; Elson, J.C.; Brown, L.; Davidson, A.C.; Konje, J.C. (2009) “Localisation and function of the endocannabinoid system in the human ovary.” PLoS One 2009;4(2):e4579. DOI: 10.1371/journal.pone.0004579
  12. Fanovich, M. A.; Churio, M. S.; Ramirez, C. L. (2020). “Medicinal cannabis: Pharmaceutical forms and recent analytical methodologies”. Comprehensive Analytical Chemistry. Analysis of Cannabis, May 2020. DOI: 10.1016/bs.coac.2020.04.001
  13. Felder, C.C.; Joyce, K.E.; Briley, E.M.; Mansouri, J.; et al. (1995) “Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.” Mol Pharmacol. 1995 Sep;48(3):443- 50. PMID: 7565624
  14. Ferber, S.G.; Namdar, D.; Hen-Shoval, D.; et al. (2020). “The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders”. Curr Neuropharmacol. 2020;18(2):87-96. PMID: 31481004 ; DOI: 10.2174/1570159X17666190903103923
  15. Gertsch, J.; Pertwee, R.G.; Di Marzo, V. (2010) “Phytocannabinoids beyond the cannabis plant—do they exist”. Br J Pharmacol. 2010;160:523–529. PMID: 20590562 ; DOI: 10.1111/j.1476-5381.2010.00745.x
  16. Hampson, A.J.; Axelrod, J.; Grimaldi, M. (2003). “Cannabinoids as antioxidants and neuroprotectants”. 1999-04-21 Application filed by US Department of Health and Human Services ; 2003-10-07 Publication of US6630507B1.
  17. Hillig, K. W. (2004). “A chemotaxonomic analysis of terpenoid variation in Cannabis.” Biochemical Systematics and Ecology, 2004, 32(10), 875–891. DOI: https://doi.org/10.1016/j.bse.2004.04.004
  18. Izzo, A.A. (2004). “Cannabinoids and intestinal motility: welcome to CB2 receptors”. British Journal of Pharmacology. 2004, 142 (8): 1201–2. PMID: 15277313 ; DOI: 10.1038/sj.bjp.0705890
  19. Izzo, A.A.; Borrelli, F.; Capasso, R.; Di Marzo, V.; Mechoulam, R.; (2009). “Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb”. Trends Pharmacol Sci. 2009 Dec;30(12):609. PMID: 19729208 ; DOI: 10.1016/j.tips.2009.07.006
  20. Laezza, C.; Pagano, C.; Navarra, G.; Pastorino, O.; Proto, M.C.; Fiore, D.; Piscopo, C.; Gazzerro, P.; Bifulco, M. (2020). “The Endocannabinoid system: A target for cancer treatment”. Int. J. Mol. Sci. 2020, 21, 747. DOI: 10.3390/ijms21030747
  21. Ligresti, A.; et al. (2006). “Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma”. J.Pharmacol. Exp. Ther. 318, 1375–1387. PMID: 16728591 ; DOI: 10.1124/jpet.106.105247
  22. Lu, H.C.; Mackie, K. (2020). “Review of the Endocannabinoid System”. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2020. DOI: https://doi.org/10.1016/j.bpsc.2020.07.016
  23. McPartland, J.M. ; Duncan, M. ; Di Marzo, V. ; et al. (2015) “Are cannabidiol and Δ-9- tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review”. Br J Pharmacol. 2015;172(3):737–753. PMID: 25257544 ; DOI: 10.1111/bph.12944
  24. Mechoulam, R. (1986). “The pharmacohistory of Cannabis sativa. In Cannabis as Therapeutic Agent”. CRC Press: Boca Raton, USA, 1986; pp. 1–19. DOI: 10.1201/9780429260667-1
  25. Mechoulam, R.; et al. (2007). “Cannabidiol recent advances”. Chem. Biodivers. 4, 1678–1692. PMID: 17712814 ; DOI: 10.1002/cbdv.200790147
  26. Mudge, E.M.; Brown, P.N.; Murch, S.J. (2019). “The terroir of cannabis: Terpene metabolomics as a tool to understand Cannabis sativa selections”. Planta Med. 2019, 85, 781–796. PMID: 31096276 ; DOI: 10.1055/a- 0915-2550
  27. Nahler, G. (2019). “Cannabidiol and Contributions of Major Hemp Phytocompounds to the “Entourage Effect”; Possible Mechanisms”. J. Altern. Complement. Med. 2019, 5, 1–16. DOI: 10.24966/ACIM-7562/100066
  28. Nallathambi, R.; Mazuz, M.; Namdar, D.; Shik, M.; Namintzer, D.; et al. (2018). “Identification of synergistic interaction between cannabis-derived compounds for cytotoxic activity in colorectal cancer cell lines and colon polyps that induces apoptosis related cell death and distinct gene expression”. Cannabis Cannabinoid Res., 2018, 31. 120-135. PMID: 29992185 ; DOI: 10.1089/can.2018.0010
  29. Namdar, D.; Voet, H.; Ajjampura, V.; Nadarajan, S.; Mayzlish-Gati, E.; Mazuz, M.; Shalev, N.; Koltai, H. (2019). “Terpenoids and phytocannabinoids co-produced in Cannabis sativa strains show specific interaction for cell cytotoxic activity”. Molecules 2019, 24, 3031. PMID: 31438532 ; DOI: 10.3390/molecules24173031
  30. Nuutinen T. (2018). “Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus”. European Journal of Medicinal Chemistry, Volume 157, 2018, Pages 198-228. PMID: 30096653 ; DOI: 10.1016/j.ejmech.2018.07.076
  31. Paduch, R.; Kandefer-Szerszeń, M.; Trytek, M.; et al. (2007) “Terpenes: substances useful in human healthcare”. Arch. Immunol. Ther. 2007, Exp. 55, 315. PMID: 18219762 ; DOI: 10.1007/s00005-007-0039- 1
  32. Peralta, L.; Agirregoitia, E.; Mendoza, R.; Expósito, A.; et al. (2011) “Expression and localization of cannabinoid receptors in human immature oocytes and unfertilized metaphase-II oocytes.” Reprod Biomed 2011;372–379. PMID: 21778114 ; DOI: 10.1016/j.rbmo.2011.05.011
  33. Pertwee, R.G. (1997). “Pharmacology of cannabinoid CB1 and CB2 receptors”. Pharmacology & Therapeutics, Volume 74, Issue 2, 1997, Pages 129-180. DOI: 10.1016/S0163-7258(97)82001-3
  34. Pertwee, R.G. (2006). “Cannabinoid pharmacology: The first 66 years”. British J Pharmacol Jan 2006; 147 (Supp 1), S163–S171. PMID: 16402100 ; DOI: 10.1038/sj.bjp.0706406
  35. Pollastro, F.; Minassi, A.; Fresu, L. G. (2018). “Cannabis Phenolics and their Bioactivities”. Current Medicinal Chemistry, 25(10), 1160–1185. PMID: 28799497 ; DOI: 10.2174/0929867324666170810164636
  36. Ramer, R.; Schwarz, R.; Hinz, B. (2019). “Modulation of the endocannabinoid system as a potential anticancer strategy.” Front. Pharmacol. 2019, 10, 430. PMID: 31143113 ; DOI: 10.3389/fphar.2019.00430
  37. Ribeiro, S. (2018). “Whole Organisms or Pure Compounds? Entourage Effect Versus Drug Specificity”. In: Labate B., Cavnar C. (eds) Plant Medicines, Healing and Psychedelic Science. 2018, Springer, Cham. DOI: 10.1007/978-3-319-76720-8_8
  38. Russo, E.B. (2011) “Taming THC. potential cannabis synergy and phytocannabinoid-terpenoid entourage effects”. British J Pharmacol 2011; 163 (7), 1344–1364. PMID: 21749363 ; DOI: 10.1111/j.1476- 5381.2011.01238.x
  39. Tyagi, V. ; Philips, B.J. ; Su, R. ; Smaldone, Tyagi, P.; et al. (2009). “Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium”. Journa l of Urology, 181, 1932–1938. PMID: 19237176 ; DOI: 10.1016/j.juro.2008.11.078
  40. Tomko, A.M.; Whynot, E.G.; Ellis, L.D.; Dupré, D.J. (2020). “Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis”. Cancers 2020, 12, 1985. PMID: 32708138 ; DOI: 10.3390/cancers12071985
  41. Touw, M. (1981). “The religious and medicinal uses of Cannabis in China, India and Tibet”. J Psychoactive Drugs. 1981;13(1):23-34. PMID: 7024492 ; DOI: 10.1080/02791072.1981.10471447
  42. Wedman-St.Louis, B. (2018). “Cannabis, A Clinician’s Guide”. (Ed.). Boca Raton: CRC Press, 2018 April 19(5):53-61. DOI: 10.1201/9780203730591
  43. Zuardi, AW. (2006). “History of cannabis as a medicine: a review”. Braz J Psychiatry. 2006 June 28(2):153- 157. PMID: 16810401 ; DOI: 10.1590/s1516-44462006000200015
  44. Zuardi, A.W. (2008). “Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action”. Rev. Bras. Psiquiatr. 30, 271–280. PMID: 18833429 ;DOI: 10.1590/s1516-44462008000300015